California lawsuit accuses drugmakers, pharmacy benefit managers of insulin overcharging
(Reuters) -California is suing the United States’ leading insulin makers and pharmacy benefit managers, accusing them of using their market power to overcharge patients for the life-saving drug, the state’s attorney general announced on Thursday.The lawsuit, filed in California Superior Court in Los Angeles, targets Eli Lilly and Co, Novo Nordisk A/S and Sanofi SA, which together make more than 90% of the insulin drugs sold globally.It also names the three largest pharmacy benefit managersContinue…